In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis
Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this dr...
Ausführliche Beschreibung
Autor*in: |
Sun, Jian [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2015 |
---|
Schlagwörter: |
---|
Anmerkung: |
© Sun et al. 2015 |
---|
Übergeordnetes Werk: |
Enthalten in: BMC veterinary research - London : BioMed Central, 2005, 11(2015), 1 vom: 01. Dez. |
---|---|
Übergeordnetes Werk: |
volume:11 ; year:2015 ; number:1 ; day:01 ; month:12 |
Links: |
---|
DOI / URN: |
10.1186/s12917-015-0604-5 |
---|
Katalog-ID: |
SPR028384431 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR028384431 | ||
003 | DE-627 | ||
005 | 20230519071025.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2015 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12917-015-0604-5 |2 doi | |
035 | |a (DE-627)SPR028384431 | ||
035 | |a (SPR)s12917-015-0604-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sun, Jian |e verfasserin |4 aut | |
245 | 1 | 0 | |a In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis |
264 | 1 | |c 2015 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Sun et al. 2015 | ||
520 | |a Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. | ||
650 | 4 | |a Marbofloxacin |7 (dpeaa)DE-He213 | |
650 | 4 | |a PK/PD |7 (dpeaa)DE-He213 | |
650 | 4 | |a CO |7 (dpeaa)DE-He213 | |
650 | 4 | |a Monte Carlo simulation |7 (dpeaa)DE-He213 | |
700 | 1 | |a Xiao, Xia |4 aut | |
700 | 1 | |a Huang, Rui-Juan |4 aut | |
700 | 1 | |a Yang, Tao |4 aut | |
700 | 1 | |a Chen, Yi |4 aut | |
700 | 1 | |a Fang, Xi |4 aut | |
700 | 1 | |a Huang, Ting |4 aut | |
700 | 1 | |a Zhou, Yu-Feng |4 aut | |
700 | 1 | |a Liu, Ya-Hong |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC veterinary research |d London : BioMed Central, 2005 |g 11(2015), 1 vom: 01. Dez. |w (DE-627)489256538 |w (DE-600)2191675-5 |x 1746-6148 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2015 |g number:1 |g day:01 |g month:12 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12917-015-0604-5 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 11 |j 2015 |e 1 |b 01 |c 12 |
author_variant |
j s js x x xx r j h rjh t y ty y c yc x f xf t h th y f z yfz y h l yhl |
---|---|
matchkey_str |
article:17466148:2015----::nirdnmchraoieipaacdnmckdtdadopomrolxc |
hierarchy_sort_str |
2015 |
publishDate |
2015 |
allfields |
10.1186/s12917-015-0604-5 doi (DE-627)SPR028384431 (SPR)s12917-015-0604-5-e DE-627 ger DE-627 rakwb eng Sun, Jian verfasserin aut In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Sun et al. 2015 Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 Xiao, Xia aut Huang, Rui-Juan aut Yang, Tao aut Chen, Yi aut Fang, Xi aut Huang, Ting aut Zhou, Yu-Feng aut Liu, Ya-Hong aut Enthalten in BMC veterinary research London : BioMed Central, 2005 11(2015), 1 vom: 01. Dez. (DE-627)489256538 (DE-600)2191675-5 1746-6148 nnns volume:11 year:2015 number:1 day:01 month:12 https://dx.doi.org/10.1186/s12917-015-0604-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2015 1 01 12 |
spelling |
10.1186/s12917-015-0604-5 doi (DE-627)SPR028384431 (SPR)s12917-015-0604-5-e DE-627 ger DE-627 rakwb eng Sun, Jian verfasserin aut In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Sun et al. 2015 Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 Xiao, Xia aut Huang, Rui-Juan aut Yang, Tao aut Chen, Yi aut Fang, Xi aut Huang, Ting aut Zhou, Yu-Feng aut Liu, Ya-Hong aut Enthalten in BMC veterinary research London : BioMed Central, 2005 11(2015), 1 vom: 01. Dez. (DE-627)489256538 (DE-600)2191675-5 1746-6148 nnns volume:11 year:2015 number:1 day:01 month:12 https://dx.doi.org/10.1186/s12917-015-0604-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2015 1 01 12 |
allfields_unstemmed |
10.1186/s12917-015-0604-5 doi (DE-627)SPR028384431 (SPR)s12917-015-0604-5-e DE-627 ger DE-627 rakwb eng Sun, Jian verfasserin aut In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Sun et al. 2015 Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 Xiao, Xia aut Huang, Rui-Juan aut Yang, Tao aut Chen, Yi aut Fang, Xi aut Huang, Ting aut Zhou, Yu-Feng aut Liu, Ya-Hong aut Enthalten in BMC veterinary research London : BioMed Central, 2005 11(2015), 1 vom: 01. Dez. (DE-627)489256538 (DE-600)2191675-5 1746-6148 nnns volume:11 year:2015 number:1 day:01 month:12 https://dx.doi.org/10.1186/s12917-015-0604-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2015 1 01 12 |
allfieldsGer |
10.1186/s12917-015-0604-5 doi (DE-627)SPR028384431 (SPR)s12917-015-0604-5-e DE-627 ger DE-627 rakwb eng Sun, Jian verfasserin aut In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Sun et al. 2015 Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 Xiao, Xia aut Huang, Rui-Juan aut Yang, Tao aut Chen, Yi aut Fang, Xi aut Huang, Ting aut Zhou, Yu-Feng aut Liu, Ya-Hong aut Enthalten in BMC veterinary research London : BioMed Central, 2005 11(2015), 1 vom: 01. Dez. (DE-627)489256538 (DE-600)2191675-5 1746-6148 nnns volume:11 year:2015 number:1 day:01 month:12 https://dx.doi.org/10.1186/s12917-015-0604-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2015 1 01 12 |
allfieldsSound |
10.1186/s12917-015-0604-5 doi (DE-627)SPR028384431 (SPR)s12917-015-0604-5-e DE-627 ger DE-627 rakwb eng Sun, Jian verfasserin aut In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Sun et al. 2015 Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 Xiao, Xia aut Huang, Rui-Juan aut Yang, Tao aut Chen, Yi aut Fang, Xi aut Huang, Ting aut Zhou, Yu-Feng aut Liu, Ya-Hong aut Enthalten in BMC veterinary research London : BioMed Central, 2005 11(2015), 1 vom: 01. Dez. (DE-627)489256538 (DE-600)2191675-5 1746-6148 nnns volume:11 year:2015 number:1 day:01 month:12 https://dx.doi.org/10.1186/s12917-015-0604-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2015 1 01 12 |
language |
English |
source |
Enthalten in BMC veterinary research 11(2015), 1 vom: 01. Dez. volume:11 year:2015 number:1 day:01 month:12 |
sourceStr |
Enthalten in BMC veterinary research 11(2015), 1 vom: 01. Dez. volume:11 year:2015 number:1 day:01 month:12 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Marbofloxacin PK/PD CO Monte Carlo simulation |
isfreeaccess_bool |
true |
container_title |
BMC veterinary research |
authorswithroles_txt_mv |
Sun, Jian @@aut@@ Xiao, Xia @@aut@@ Huang, Rui-Juan @@aut@@ Yang, Tao @@aut@@ Chen, Yi @@aut@@ Fang, Xi @@aut@@ Huang, Ting @@aut@@ Zhou, Yu-Feng @@aut@@ Liu, Ya-Hong @@aut@@ |
publishDateDaySort_date |
2015-12-01T00:00:00Z |
hierarchy_top_id |
489256538 |
id |
SPR028384431 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR028384431</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519071025.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12917-015-0604-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR028384431</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12917-015-0604-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sun, Jian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Sun et al. 2015</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Marbofloxacin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PK/PD</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CO</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Monte Carlo simulation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiao, Xia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Rui-Juan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Tao</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Yi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fang, Xi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Ting</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Yu-Feng</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Ya-Hong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC veterinary research</subfield><subfield code="d">London : BioMed Central, 2005</subfield><subfield code="g">11(2015), 1 vom: 01. Dez.</subfield><subfield code="w">(DE-627)489256538</subfield><subfield code="w">(DE-600)2191675-5</subfield><subfield code="x">1746-6148</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">day:01</subfield><subfield code="g">month:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12917-015-0604-5</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="b">01</subfield><subfield code="c">12</subfield></datafield></record></collection>
|
author |
Sun, Jian |
spellingShingle |
Sun, Jian misc Marbofloxacin misc PK/PD misc CO misc Monte Carlo simulation In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis |
authorStr |
Sun, Jian |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)489256538 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1746-6148 |
topic_title |
In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 |
topic |
misc Marbofloxacin misc PK/PD misc CO misc Monte Carlo simulation |
topic_unstemmed |
misc Marbofloxacin misc PK/PD misc CO misc Monte Carlo simulation |
topic_browse |
misc Marbofloxacin misc PK/PD misc CO misc Monte Carlo simulation |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
BMC veterinary research |
hierarchy_parent_id |
489256538 |
hierarchy_top_title |
BMC veterinary research |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)489256538 (DE-600)2191675-5 |
title |
In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis |
ctrlnum |
(DE-627)SPR028384431 (SPR)s12917-015-0604-5-e |
title_full |
In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis |
author_sort |
Sun, Jian |
journal |
BMC veterinary research |
journalStr |
BMC veterinary research |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2015 |
contenttype_str_mv |
txt |
author_browse |
Sun, Jian Xiao, Xia Huang, Rui-Juan Yang, Tao Chen, Yi Fang, Xi Huang, Ting Zhou, Yu-Feng Liu, Ya-Hong |
container_volume |
11 |
format_se |
Elektronische Aufsätze |
author-letter |
Sun, Jian |
doi_str_mv |
10.1186/s12917-015-0604-5 |
title_sort |
in vitro dynamic pharmacokinetic/pharamcodynamic (pk/pd) study and $ co_{pd} $ of marbofloxacin against haemophilus parasuis |
title_auth |
In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis |
abstract |
Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. © Sun et al. 2015 |
abstractGer |
Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. © Sun et al. 2015 |
abstract_unstemmed |
Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. © Sun et al. 2015 |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
1 |
title_short |
In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis |
url |
https://dx.doi.org/10.1186/s12917-015-0604-5 |
remote_bool |
true |
author2 |
Xiao, Xia Huang, Rui-Juan Yang, Tao Chen, Yi Fang, Xi Huang, Ting Zhou, Yu-Feng Liu, Ya-Hong |
author2Str |
Xiao, Xia Huang, Rui-Juan Yang, Tao Chen, Yi Fang, Xi Huang, Ting Zhou, Yu-Feng Liu, Ya-Hong |
ppnlink |
489256538 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/s12917-015-0604-5 |
up_date |
2024-07-03T19:08:57.243Z |
_version_ |
1803586096066461696 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR028384431</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519071025.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12917-015-0604-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR028384431</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12917-015-0604-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sun, Jian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Sun et al. 2015</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Marbofloxacin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PK/PD</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CO</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Monte Carlo simulation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiao, Xia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Rui-Juan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Tao</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Yi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fang, Xi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Ting</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Yu-Feng</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Ya-Hong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC veterinary research</subfield><subfield code="d">London : BioMed Central, 2005</subfield><subfield code="g">11(2015), 1 vom: 01. Dez.</subfield><subfield code="w">(DE-627)489256538</subfield><subfield code="w">(DE-600)2191675-5</subfield><subfield code="x">1746-6148</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">day:01</subfield><subfield code="g">month:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12917-015-0604-5</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="b">01</subfield><subfield code="c">12</subfield></datafield></record></collection>
|
score |
7.3992815 |